London‑based pharma major AstraZeneca has reported that its liver‑cancer therapy combination, built around its immunotherapy Imfinzi (durvalumab), significantly slowed disease progression in patients with unresectable hepatocellular carcinoma (HCC) in a late‑stage trial, reinforcing its role in India’s growing oncology landscape.
The data come from the EMERALD‑3 Phase III trial, which evaluated a regimen of Imfinzi plus Imjudo (tremelimumab), with or without the TKI lenvatinib, alongside transarterial chemoembolisation (TACE) in patients with HCC eligible for embolisation. The regimen met its primary endpoint of progression‑free survival (PFS), halting or delaying disease progression for a significantly longer period than TACE alone.
Hepatocellular carcinoma accounts for roughly 75% of adult primary liver cancers, and many patients in India present at an unresectable stage, where TACE is commonly used but carries a high risk of recurrence. By adding Imfinzi‑ and Imjudo‑based immunotherapy to TACE, the EMERALD‑3 regimen reduced the risk of progression or death, with interim analysis pointing to a trend toward improved overall survival, though final OS data are still maturing.
The combination tested, known as the STRIDE regimen (Single Tremelimumab Regular Interval Durvalumab), was given before and during TACE, integrating systemic immunotherapy with locoregional therapy in a single‑protocol approach. Across 760 patients enrolled at 171 centres in 22 countries, the safety profile of the combination was consistent with the known profiles of the individual agents, without new safety signals.
For India, where liver‑cancer rates are rising due to hepatitis B/C, fatty‑liver disease, and alcohol‑related liver damage, the results could open doors to earlier integration of checkpoint‑based immunotherapy into embolisation‑based treatment pathways. If approved, this strategy may allow Indian oncology centres to move beyond TACE‑only control and offer patients a more durable, systemic‑plus‑interventional approach that delays progression and potentially extends survival.
“This combination is designed to tackle the high recurrence rates seen after TACE by combining potent immunotherapy with established locoregional control,” said an AstraZeneca statement summarising the EMERALD‑3 findings. Experts in the global hepatology community have described the data as a step toward reshaping the standard‑of‑care paradigm for unresectable HCC, particularly in embolisation‑eligible patients who historically lacked effective systemic options in this setting.
AstraZeneca plans to discuss the EMERALD‑3 results with regulatory authorities worldwide, with potential label expansions for Imfinzi and Imjudo in HCC on the horizon. For Indian oncologists and hepatologists, the data bolster the case for immunotherapy‑TACE combinations in carefully selected liver‑cancer cohorts, while also highlighting the need for improved hepatitis screening, early detection, and access to advanced therapeutics across the country.
